Myelodysplastic Syndromes (MDS)
Nutrition for Patients with Aplastic Anemia, MDS, or PNH
Advances and challenges in the treatment of myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Purpose: Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor.
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review
Allogeneic hematopoietic stem-cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher-risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and molecular heterogeneity, necessitating personalized approaches to patient selection, timing, and transplant management. For MDS, genomic profiling has revolutionized prognostic frameworks such as IPSS-M, enabling tailored therapeutic decisions.
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PL
Germline and somatic genetic landscape of pediatric myelodysplastic syndromes
Pediatric myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders wher
